Evercore ISI Group Maintains In-Line on NovoCure, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Vijay Kumar maintains an In-Line rating on NovoCure (NASDAQ:NVCR) and raises the price target from $14.5 to $20.
July 02, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group analyst Vijay Kumar maintains an In-Line rating on NovoCure and raises the price target from $14.5 to $20.
The raised price target from $14.5 to $20 by a reputable analyst suggests a positive outlook for NovoCure, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100